Capricor Therapeutics (NASDAQ:CAPR) CFO Sells $732,158.00 in Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 24,100 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the completion of the transaction, the chief financial officer owned 11,223 shares in the company, valued at $340,954.74. This represents a 68.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Anthony Bergmann also recently made the following trade(s):

• On Monday, June 22nd, Anthony Bergmann sold 500 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $15,000.00.
• On Wednesday, June 24th, Anthony Bergmann sold 400 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $12,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.70, for a total value of $792,500.00.

Capricor Therapeutics Trading Down 10.0%

CAPR stock opened at $23.80 on Tuesday. The company’s 50 day moving average is $29.79 and its 200 day moving average is $28.39. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -10.26 and a beta of 0.39. Capricor Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, sell-side analysts forecast that Capricor Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Institutional Trading of Capricor Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its stake in Capricor Therapeutics by 12.4% in the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 557 shares during the period. KBC Group NV purchased a new stake in shares of Capricor Therapeutics during the first quarter valued at approximately $44,000. ACT Capital Management LLC purchased a new stake in shares of Capricor Therapeutics during the fourth quarter valued at approximately $43,000. Nuveen LLC boosted its stake in shares of Capricor Therapeutics by 2.1% during the fourth quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock valued at $2,625,000 after purchasing an additional 1,878 shares during the period. Finally, State of Wyoming grew its holdings in shares of Capricor Therapeutics by 76.0% in the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 1,913 shares during the last quarter. 21.68% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CAPR has been the topic of a number of research analyst reports. Roth Mkm reissued a “buy” rating and issued a $38.00 target price on shares of Capricor Therapeutics in a research note on Friday, May 15th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. LADENBURG THALM/SH SH upgraded Capricor Therapeutics to a “strong-buy” rating in a research report on Thursday, June 25th. B. Riley Financial boosted their target price on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $53.67.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.